一种针对多发性骨髓瘤的抗B细胞成熟抗原双特异抗体
Nitya S Ramadoss1, Andrew D Schulman1, Sei-hyun Choi
1†California Institute for Biomedical Research, 11119 North Torrey Pines Road, Suite 100, La Jolla, California 92037, United States.
Journal of the American Chemical Society
|April 1, 2015
概括
一种针对B细胞成熟抗原的新双特异性抗体 (BiFab-BCMA) 通过重定向T细胞,有效地消除多发性髓瘤细胞. 这种免疫疗法表现出与CAR-T-BCMA相当的强大活性,提供了一个有前途的治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 多发性骨髓瘤的治疗面临着由于耐药性的挑战.
- 开发新型免疫疗法对于克服耐药性至关重要.
- B细胞成熟抗原 (BCMA) 是多发性骨髓瘤的一个关键点.
研究的目的:
- 开发和评估针对多发性骨髓瘤的针对BCMA (BiFab-BCMA) 的双特异性抗体.
- 在体外和体内评估BiFab-BCMA的疗效和强度.
- 将BiFab-BCMA与其他针对BCMA的治疗方法进行比较.
主要方法:
- 开发一种针对BCMA的双特异性抗体 (BiFab-BCMA).
- 在体外评估BCMA阳性多发性髓瘤细胞的T细胞重定向和溶解.
- 在多发性骨髓瘤的正位异种移植模型中的体内评估.
- 与针对CS1的双特异性抗体 (BiFab-CS1) 和抗BCMA化学抗原受体T细胞疗法 (CAR-T-BCMA) 的比较.
主要成果:
- BiFab-BCMA证明了多发性骨髓瘤细胞的强大和特异性溶解.
- 它的效果比BiFab-CS1.1高出20倍.
- 在体外,BiFab-BCMA强烈激活了T细胞,并在体内促进了瘤的快速回归.
- 实验室和体内活动与CAR-T-BCMA相似.
结论:
- BiFab-BCMA是一种针对多发性骨髓瘤的强效免疫疗法.
- 它有效地重定向T细胞以消除恶性细胞.
- 针对BCMA的双特异性抗体代表了对多发性骨髓瘤的有希望的治疗选择.
相关概念视频
Hybridoma Technology
18.7K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
18.7K
B Cell Activation and Differentiation
18.7K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
18.7K
Diversity of Antigen Receptors
2.2K
Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
2.2K


